These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9226005)

  • 21. Selective inhibition of HIV replication by adriamycin in macrophages but not in lymphocytes.
    Bergamini A; Perno CF; Balzarini J; Capozzi M; Marinelli L; Milanese G; Pesce CD; Calió R; Rocchi G
    AIDS Res Hum Retroviruses; 1992 Jul; 8(7):1239-47. PubMed ID: 1381599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-human immunodeficiency virus type 1 (HIV-1) activity of 2'-fluoro-2',3'-dideoxyarabinosyladenine (F-ddA) used in combination with other mechanistically diverse inhibitors of HIV-1 replication.
    Buckheit RW; Russell JD; Pallansch LA; Driscoll JS
    Antivir Chem Chemother; 1999 May; 10(3):115-9. PubMed ID: 10431610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase.
    De Clercq E
    Med Res Rev; 1993 May; 13(3):229-58. PubMed ID: 7683360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
    Cushman M; Casimiro-Garcia A; Hejchman E; Ruell JA; Huang M; Schaeffer CA; Williamson K; Rice WG; Buckheit RW
    J Med Chem; 1998 Jun; 41(12):2076-89. PubMed ID: 9622549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suksdorfin: an anti-HIV principle from Lomatium suksdorfii, its structure-activity correlation with related coumarins, and synergistic effects with anti-AIDS nucleosides.
    Lee TT; Kashiwada Y; Huang L; Snider J; Cosentino M; Lee KH
    Bioorg Med Chem; 1994 Oct; 2(10):1051-6. PubMed ID: 7773621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efavirenz is a potent nonnucleoside reverse transcriptase inhibitor of HIV type 1 replication in microglia in vitro.
    Albright AV; Erickson-Viitanen S; O'Connor M; Frank I; Rayner MM; González-Scarano F
    AIDS Res Hum Retroviruses; 2000 Oct; 16(15):1527-37. PubMed ID: 11054266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines.
    Perno CF; Balestra E; Aquaro S; Panti S; Cenci A; Lazzarino G; Tavazzi B; Di Pierro D; Balzarini J; Calio R
    Mol Pharmacol; 1996 Aug; 50(2):359-66. PubMed ID: 8700144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-HIV efficacy and biodistribution of nucleoside reverse transcriptase inhibitors delivered as squalenoylated prodrug nanoassemblies.
    Hillaireau H; Dereuddre-Bosquet N; Skanji R; Bekkara-Aounallah F; Caron J; Lepêtre S; Argote S; Bauduin L; Yousfi R; Rogez-Kreuz C; Desmaële D; Rousseau B; Gref R; Andrieux K; Clayette P; Couvreur P
    Biomaterials; 2013 Jul; 34(20):4831-8. PubMed ID: 23562054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cellular pharmacology and potency of HIV-1 nucleoside analogs in primary human macrophages.
    Gavegnano C; Detorio MA; Bassit L; Hurwitz SJ; North TW; Schinazi RF
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1262-9. PubMed ID: 23263005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Correlation between HIV-inhibiting drug activity in human macrophages and clinical outcome].
    Aquaro S; Balestra E; Panti S; Cenci A; Serra F; Francesconi M; Abdelahad D; Caliò R; Perno CF
    Clin Ter; 1998; 149(921):37-41. PubMed ID: 9621487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ability of anti-HIV agents to inhibit HIV replication in monocyte/macrophages or U937 monocytoid cells under conditions of enhancement by GM-CSF or anti-HIV antibody.
    Perno CF; Cooney DA; Currens MJ; Rocchi G; Johns DG; Broder S; Yarchoan R
    AIDS Res Hum Retroviruses; 1990 Aug; 6(8):1051-5. PubMed ID: 2223241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Favorable interaction of beta-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus.
    Bridges EG; Dutschman GE; Gullen EA; Cheng YC
    Biochem Pharmacol; 1996 Mar; 51(6):731-6. PubMed ID: 8602867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Inhibition of alfa interferon and ampligen of human immunodeficiency virus (HIV) replication in monocyte-macrophage subpopulations].
    Bergamini A; Ercoli L; Perno CF
    Medicina (Firenze); 1990; 10(1):34-6. PubMed ID: 2381279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages.
    Aquaro S; Svicher V; Ceccherini-Silberstein F; Cenci A; Marcuccilli F; Giannella S; Marcon L; Caliò R; Balzarini J; Perno CF
    J Antimicrob Chemother; 2005 Jun; 55(6):872-8. PubMed ID: 15845785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antisense phosphorothioate oligodeoxynucleotides alter HIV type 1 replication in cultured human macrophages and peripheral blood mononuclear cells.
    Weichold FF; Lisziewicz J; Zeman RA; Nerurkar LS; Agrawal S; Reitz MS; Gallo RC
    AIDS Res Hum Retroviruses; 1995 Jul; 11(7):863-7. PubMed ID: 7546914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido-2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine.
    Perno CF; Yarchoan R; Cooney DA; Hartman NR; Webb DS; Hao Z; Mitsuya H; Johns DG; Broder S
    J Exp Med; 1989 Mar; 169(3):933-51. PubMed ID: 2538549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
    Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
    J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activities of masked 2',3'-dideoxynucleoside monophosphate derivatives against human immunodeficiency virus in resting macrophages.
    Aquaro S; Wedgwood O; Yarnold C; Cahard D; Pathinara R; McGuigan C; Calio' R; de Clercq E; Balzarini J; Perno CF
    Antimicrob Agents Chemother; 2000 Jan; 44(1):173-7. PubMed ID: 10602742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nano-NRTIs: efficient inhibitors of HIV type-1 in macrophages with a reduced mitochondrial toxicity.
    Vinogradov SV; Poluektova LY; Makarov E; Gerson T; Senanayake MT
    Antivir Chem Chemother; 2010 Oct; 21(1):1-14. PubMed ID: 21045256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.